Complete your stack
- GLO (TB-500 + BPC-157 + Copper GHk Peptide Blend) $109.99
- Tirzepatide $109.99 Coming soon
- YK11 - Myostine $109.99
Retatrutide
$109.99
Retatrutide Canada, the next-generation triple-agonist research peptide (GLP-1 + GIP + glucagon) in one molecule. Lab-tested, high-purity Canadian peptides shipped fast for laboratory and educational use only.
Description
Retatrutide is the most talked-about metabolic research peptide of its generation, and for good reason: it is the first single-molecule triple hormone-receptor agonist, engaging the GLP-1, GIP, and glucagon pathways at once to drive results that outpaced every prior class in controlled trials. Sourced as high-purity, lab-verified Canadian peptides and shipped quickly across the country, Helixx offers Retatrutide Canada researchers a next-generation reference compound for serious metabolic and body-composition investigation, supplied strictly for laboratory and educational use only.1
What Is Retatrutide?
Retatrutide (research code LY3437943) is a synthetic single-molecule peptide engineered as a balanced triple agonist of three key incretin and metabolic hormone receptors: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon (GCG) receptor. This three-pathway design sets it apart from single-pathway GLP-1 agonists such as Ozempic (Semaglutide) and from dual GIP/GLP-1 agonists such as Tirzepatide. With a terminal half-life of roughly 5-7 days, it was characterized in preclinical and first-in-human work as a once-weekly subcutaneous candidate.1 It remains an investigational compound and is not an approved medicine; Helixx supplies it as a research chemical only.
How Retatrutide Works
Retatrutide’s defining feature is simultaneous, balanced activation of three receptors. GLP-1 and GIP receptor agonism promote glucose-dependent insulin secretion, slow gastric emptying, and reduce appetite and caloric intake, which are the mechanisms behind the improved glycemic control and weight reduction seen across the incretin class.1 The added glucagon-receptor agonism is what distinguishes the molecule: it increases energy expenditure and stimulates hepatic lipolysis and fat oxidation, augmenting weight loss and sharply reducing hepatic fat. The concurrent GLP-1/GIP insulinotropic activity offsets glucagon’s natural tendency to raise blood glucose, so the net metabolic effect stays favourable. This three-pathway architecture is the rationale for studying Retatrutide as a next-generation alternative to earlier single- and dual-pathway agonists.1
What the Research Shows
- Discovery and first-in-human. The foundational characterization paper confirmed balanced agonism at all three receptors, demonstrated glucose- and weight-lowering in preclinical models, and reported a ~5-7 day half-life supporting weekly dosing, with mostly mild, dose-dependent gastrointestinal events.1
- Obesity (Phase 2). In a randomized, double-blind trial of 338 adults with obesity or overweight without diabetes, the highest dose (12 mg) produced a mean body-weight reduction of about 24.2% at 48 weeks versus 2.1% with placebo; adverse events were predominantly gastrointestinal and dose-related.2
- Type 2 diabetes (Phase 2). In adults with type 2 diabetes, Retatrutide produced dose-dependent HbA1c reductions of up to roughly 2.0 percentage points alongside substantial weight loss, exceeding placebo and active comparators.3
- Liver fat / MASLD (Phase 2a). In a sub-study of 98 participants with metabolic dysfunction-associated steatotic liver disease, mean relative liver-fat reductions ranged from 42.9% to 82.4% across doses at 24 weeks versus 0.3% with placebo, with no hepatotoxicity signal through 48 weeks.4
- Pooled safety. A systematic review and meta-analysis of randomized trials found significantly elevated, dose-dependent rates of nausea, vomiting, diarrhea, constipation, and decreased appetite versus placebo, while judging the overall safety profile generally favourable and consistent with the GLP-1 agonist class.5
Researchers comparing incretin pathways often benchmark Retatrutide against Tirzepatide and Ozempic (Semaglutide), or study it alongside recovery and body-composition peptides such as AOD9604 and MOTS-c within broader metabolic research programs.
Chemical Properties
| Research Name | Retatrutide (LY3437943) |
| CAS Number | 2381089-83-2 |
| Molecular Formula | C335H508N88O98 |
| Molecular Weight | 7559 g/mol |
| Classification | Triple receptor agonist peptide (GLP-1 / GIP / glucagon) |
Research Protocols & Handling
This product is supplied strictly as a research chemical for in-vitro laboratory and educational use only. It is not for human or veterinary use, not for consumption, and not intended to diagnose, treat, cure, or prevent any condition. Lyophilized peptide should be stored cold and protected from light: refrigerate at 2-8°C for short-term handling, and freeze (-20°C or below) for long-term storage. Reconstitution with bacteriostatic water is standard practice in laboratory settings; once reconstituted, keep it refrigerated and use it within a limited window. Handle using appropriate laboratory technique, avoid repeated freeze-thaw cycles, and keep the material out of reach of children and unqualified persons. Researchers are responsible for compliance with all applicable institutional and legal requirements.
Potential Side Effects & Safety
Although Retatrutide is a research compound and not for human use, the clinical literature documents a clear adverse-event profile that researchers should understand. The following effects were observed in human trials or are class-plausible for incretin agonists:
- Nausea. Very common and dose-dependent, most frequent during dose escalation; partly mitigated in trials by a lower starting dose.2
- Vomiting, diarrhea, and constipation. Common, dose-related gastrointestinal events, mostly mild-to-moderate across studies.5
- Decreased appetite. Consistently and significantly elevated versus placebo, reflecting the compound’s appetite-suppressing mechanism.5
- Abdominal distention, dyspepsia, and abdominal discomfort. Reported in trials, generally transient.1
- Dose-dependent increase in heart rate. Observed in the obesity trial and typical of the class.2
- Transient increases in blood glucose. Seen at higher doses in some participants, attributed to glucagon-receptor activity.3
- Cutaneous hyperesthesia / dysesthesia. Skin sensitivity reported in some trials.2
- Injection-site reactions. Class-plausible for subcutaneous peptide agonists.
- Hypoglycemia risk. Class-plausible when combined with insulin or sulfonylureas.
- Gallbladder-related events and acute pancreatitis. Recognized class-plausible risks of incretin agonists.
- Rare serious adverse events. Uncommon overall, but discontinuations due to adverse events increase at higher doses.5
Not approved for human consumption in Canada or elsewhere; research and educational use only.
Frequently Asked Questions
Is Retatrutide legal in Canada?
Retatrutide is not an approved drug in Canada and is not authorized for human or veterinary use. It may be bought and sold as a research chemical for laboratory and educational purposes only. Helixx supplies Retatrutide Canada researchers with material intended strictly for in-vitro study, not for consumption, and buyers are responsible for compliance with applicable regulations.
How does Retatrutide differ from Tirzepatide and Semaglutide?
Semaglutide targets a single receptor (GLP-1) and Tirzepatide targets two (GIP and GLP-1). Retatrutide adds a third, the glucagon receptor, which makes it a triple agonist. That added glucagon activity is associated with increased energy expenditure and reduced hepatic fat in research settings.1 You can compare the single-pathway option at Ozempic (Semaglutide).
What did the obesity research demonstrate?
In a randomized Phase 2 trial, the highest 12 mg dose produced a mean body-weight reduction of about 24.2% at 48 weeks versus 2.1% with placebo, with predominantly gastrointestinal, dose-related adverse events.2 These are research findings only and are not a claim of any effect in humans outside a controlled study.
How are Canadian peptides from Helixx stored and shipped?
Our Canadian peptides are supplied lyophilized for stability and shipped domestically for fast delivery. Store the vial cold and protected from light (refrigerated for short-term use or frozen for longer-term storage), and reconstitute with bacteriostatic water using proper laboratory technique when required for research. Researchers exploring broader peptide programs often pair metabolic study compounds with recovery blends such as GLO (TB-500 + BPC-157 + Copper GHK Peptide Blend).
References
Peer-reviewed and authoritative sources cited above. Helixx supplies research materials for laboratory and educational use only; citations are provided for independent verification, not as medical guidance.
- Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234-1247.e9. PMID: 35985340.
- Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. PMID: 37366315.
- Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529-544. PMID: 37385280.
- Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30(7):2037-2048. PMID: 38858523.
- Abouelmagd AA, Abdelrehim AM, Bashir MN, et al. Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials. Proc (Bayl Univ Med Cent). 2025;38(3):291-303. PMID: 40291085.